Clinical trials
Phase 2 Multiple Myeloma trials with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
67 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 3 |
| 2004 | 1 |
| 2005 | 5 |
| 2006 | 5 |
| 2007 | 1 |
| 2008 | 2 |
| 2010 | 2 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 3 |
| 2014 | 3 |
| 2015 | 2 |
| 2017 | 2 |
| 2018 | 8 |
| 2019 | 5 |
| 2020 | 2 |
| 2021 | 5 |
| 2022 | 7 |
| 2023 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 67 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hellenic Society of Hematology | 4 |
| Korean Multiple Myeloma Working Party | 3 |
| Samsung Medical Center | 3 |
| Azienda Ospedaliera San Giovanni Battista | 2 |
| Chonnam National University Hospital | 2 |
| Henrik Gregersen | 2 |
| Herbert Irving Comprehensive Cancer Center | 2 |
| Medical College of Wisconsin | 2 |
| Nordic Myeloma Study Group | 2 |
| Assistance Publique - Hôpitaux de Paris | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Multiple Myeloma | 67 |
| Neoplasms, Plasma Cell | 18 |
| Lymphoma | 10 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 9 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 9 |
| Leukemia | 8 |
| Leukemia, Myeloid, Acute | 7 |
| Lymphoma, Non-Hodgkin | 7 |
| Myelodysplastic Syndromes | 7 |
| Burkitt Lymphoma | 6 |
Trials
Showing 1 to 25 of 67. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.